Antineoplastic therapy-induced pulmonary toxicity

被引:7
作者
Sadowska, Anna M. [1 ]
Specenier, Pol [2 ]
Germonpre, Paul [3 ]
Peeters, Marc [2 ]
机构
[1] Ziekenuis Maas Kempen, Dept Resp Med, B-3680 Maaseik, Belgium
[2] Univ Hosp Antwerpen, Dept Med Oncol, B-2650 Edegem, Belgium
[3] AZ Maria Middelares, Dept Resp Med, B-9000 Ghent, Belgium
关键词
antineoplastic therapy; pneumonitis; pulmonary toxicity; CELL LUNG-CANCER; PHASE-II TRIAL; INDUCED HYPERSENSITIVITY PNEUMONITIS; HIGH-DOSE CYCLOPHOSPHAMIDE; INTERSTITIAL PNEUMONITIS; BRONCHOALVEOLAR LAVAGE; EOSINOPHILIC PNEUMONIA; COLORECTAL-CANCER; PLEURAL EFFUSION; PLUS CARBOPLATIN;
D O I
10.1586/14737140.2013.817684
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is complex and should be based on the medical history, clinical, radiological and pathological findings. None of them are specific but they can guide the diagnostic process. The treatment of pulmonary abnormalities caused by chemotherapy is mostly supportive and based on cessation of the causative agent. However, the therapeutic options in oncology setting are usually limited thus the decision about changing the treatment should be taken with caution.
引用
收藏
页码:997 / 1006
页数:10
相关论文
共 126 条
[31]  
GOULD VE, 1975, AM J PATHOL, V81, P513
[32]  
Grahmann P R, 2005, Pneumologie, V59, P763, DOI 10.1055/s-2005-919069
[33]   Fatal pulmonary toxicity after a single dose of cyclophosphamide [J].
Gupta, Shilpa ;
Mahipal, Amit .
PHARMACOTHERAPY, 2007, 27 (04) :616-618
[34]  
HAINER BL, 1981, J FAM PRACTICE, V13, P817
[35]   PULMONARY TOXICITY RECURRING AFTER A 6 WEEK COURSE OF BUSULFAN THERAPY AND AFTER SUBSEQUENT THERAPY WITH URACIL MUSTARD [J].
HANKINS, DG ;
SANDERS, S ;
MACDONALD, FM ;
DRAGE, CW .
CHEST, 1978, 73 (03) :415-416
[36]   ENHANCED PULMONARY TOXICITY IN SMOKERS WITH GERM-CELL CANCER TREATED WITH CIS-PLATINUM, VINBLASTINE AND BLEOMYCIN - A LONG-TERM FOLLOW-UP [J].
HANSEN, SW ;
GROTH, S ;
SORENSEN, PG ;
ROSSING, N ;
RORTH, M .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (04) :733-736
[37]   LIFE-THREATENING BLEOMYCIN PULMONARY TOXICITY WITH ULTIMATE REVERSIBILITY [J].
HARTMANN, LC ;
FRYTAK, S ;
RICHARDSON, RL ;
COLES, DT ;
CUPPS, RE .
CHEST, 1990, 98 (02) :497-499
[38]   Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab? [J].
Herbst, RS ;
Sandler, AB .
ONCOLOGIST, 2004, 9 :19-26
[39]   Interstitial Pneumonitis and Alveolar Hemorrhage Complicating Use of Rituximab [J].
Heresi, Gustavo A. ;
Farver, Carol F. ;
Stoller, James K. .
RESPIRATION, 2008, 76 (04) :449-453
[40]  
Hilliquin P, 1996, BRIT J RHEUMATOL, V35, P441